Enanta Pharma (ENTA) Misses Q1 EPS by 8c

Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of ($0.26), $0.08 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Humana reaffirms 2026 earnings guidance ahead of investor meetings